Ha habido 50 transacciones internas recientes registradas para Ventyx Biosciences, Inc. (VTYX), incluyendo 24 compras y 24 ventas. El total de compras internas fue valorado en $7M y el total de ventas internas en $2.56M.
Internos destacados con actividad reciente incluyen Subramaniam Somu, Hulme Allison, Gujrathi Sheila. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — VTYX
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2025-06-05 |
Subramaniam Somu |
Director |
Concesión de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Hulme Allison |
Director |
Concesión de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Gujrathi Sheila |
Director |
Concesión de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
White William Richard |
Director |
Concesión de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Cadoret-manier Onaiza |
Director |
Concesión de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-05-15 |
Forman Mark S |
Chief Medical Officer |
Concesión de RSU |
3,000 |
$1.03 |
$3.09K |
3,000 |
| 2025-05-15 |
Gonzales Roy |
Senior VP, Finance |
Concesión de RSU |
1,750 |
$1.03 |
$1.8K |
3,546 |
| 2025-04-02 |
Nuss John |
Chief Scientific Officer |
Venta Informativa |
1,887 |
$1.07 |
$2.02K |
467,226 |
| 2025-03-28 |
Subramaniam Somu |
Director |
Otro (Venta) |
1,335,450 |
- |
- |
4,032,213 |
| 2025-03-28 |
Nuss John |
Chief Scientific Officer |
Ejercicio de Opciones (Venta) |
4,531 |
- |
- |
9,063 |
| 2025-03-28 |
Mohan Raju |
CEO and President |
Ejercicio de Opciones (Venta) |
11,844 |
- |
- |
23,688 |
| 2025-03-10 |
Subramaniam Somu |
Director |
Otro (Venta) |
1,735,306 |
- |
- |
5,367,663 |
| 2025-01-02 |
Moore Matthew Richard |
Chief Operating Officer |
Concesión de RSU |
145,000 |
$2.14 |
$310.3K |
145,000 |
| 2025-01-02 |
Nuss John |
Chief Scientific Officer |
Concesión de RSU |
170,104 |
$2.14 |
$364.02K |
170,104 |
| 2025-01-02 |
Mohan Raju |
CEO and President |
Concesión de RSU |
700,000 |
$2.14 |
$1.5M |
700,000 |
| 2025-01-02 |
Forman Mark S |
Chief Medical Officer |
Concesión de RSU |
85,000 |
$2.14 |
$181.9K |
85,000 |
| 2025-01-02 |
Gonzales Roy |
Senior VP, Finance |
Concesión de RSU |
17,500 |
$2.14 |
$37.45K |
17,500 |
| 2024-12-27 |
Nuss John |
Chief Scientific Officer |
Venta Informativa |
21,119 |
$2.36 |
$49.84K |
464,582 |
| 2024-12-23 |
Gujrathi Sheila |
Director |
Compra Informativa |
130,000 |
$2.31 |
$300.57K |
130,000 |
| 2024-12-19 |
Nuss John |
Chief Scientific Officer |
Venta Informativa |
13,161 |
$2.26 |
$29.68K |
485,701 |
| 2024-12-17 |
Nuss John |
Chief Scientific Officer |
Ejercicio de Opciones (Venta) |
34,930 |
- |
- |
34,930 |
| 2024-12-17 |
Mohan Raju |
CEO and President |
Ejercicio de Opciones (Venta) |
116,668 |
- |
- |
116,668 |
| 2024-12-10 |
Nuss John |
Chief Scientific Officer |
Ejercicio de Opciones (Venta) |
193,557 |
$0.20 |
$38.71K |
- |
| 2024-11-25 |
Mohan Raju |
CEO and President |
Compra Informativa |
261,752 |
$2.01 |
$524.94K |
2,175,028 |
| 2024-11-22 |
Mohan Raju |
CEO and President |
Compra Informativa |
238,248 |
$1.83 |
$434.95K |
1,913,276 |
| 2024-08-30 |
Gonzales Roy |
Senior VP, Finance |
Disposición |
70,000 |
$33.84 |
$2.37M |
- |
| 2024-08-12 |
Forman Mark S |
Officer |
Desconocido |
- |
- |
- |
- |
| 2024-08-12 |
Forman Mark S |
Chief Medical Officer |
Concesión de RSU |
350,000 |
$1.95 |
$682.5K |
350,000 |
| 2024-06-24 |
Subramaniam Somu |
10 Percent Owner |
Otro (Venta) |
641,327 |
- |
- |
7,102,969 |
| 2024-06-24 |
Nsv Partners Iii Lp |
10 Percent Owner |
Otro (Venta) |
641,327 |
- |
- |
7,102,969 |
| 2024-06-10 |
Mohan Raju |
CEO and President |
Ejercicio de Opciones (Venta) |
96,778 |
$0.20 |
$19.36K |
- |
| 2024-06-06 |
Subramaniam Somu |
10 Percent Owner |
Concesión de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Hulme Allison |
Director |
Concesión de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Gujrathi Sheila |
Director |
Concesión de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
White William Richard |
Director |
Concesión de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Cadoret-manier Onaiza |
Director |
Concesión de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-05-16 |
Moore Matthew Richard |
Officer |
Desconocido |
- |
- |
- |
- |
| 2024-05-16 |
Moore Matthew Richard |
Chief Operating Officer |
Concesión de RSU |
320,000 |
$4.98 |
$1.59M |
320,000 |
| 2024-04-12 |
Subramaniam Somu |
10 Percent Owner |
Otro (Venta) |
695,339 |
- |
- |
7,744,296 |
| 2024-04-12 |
Nsv Partners Iii Lp |
10 Percent Owner |
Otro (Venta) |
695,339 |
- |
- |
7,744,296 |
| 2024-04-02 |
Krueger Christopher W |
Chief Business Officer |
Venta Informativa |
1,651 |
$5.40 |
$8.92K |
284,999 |
| 2024-04-02 |
Nuss John |
Chief Scientific Officer |
Venta Informativa |
1,651 |
$5.40 |
$8.92K |
264,998 |
| 2024-04-02 |
Auster Martin |
Chief Financial Officer |
Venta Informativa |
1,405 |
$5.40 |
$7.59K |
24,303 |
| 2024-04-02 |
Mohan Raju |
CEO and President |
Venta Informativa |
4,312 |
$5.40 |
$23.3K |
1,578,250 |
| 2024-03-28 |
Krueger Christopher W |
Chief Business Officer |
Ejercicio de Opciones (Venta) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Nuss John |
Chief Scientific Officer |
Ejercicio de Opciones (Venta) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Auster Martin |
Chief Financial Officer |
Ejercicio de Opciones (Venta) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Mohan Raju |
CEO and President |
Ejercicio de Opciones (Venta) |
11,843 |
- |
- |
35,532 |
| 2024-01-21 |
Subramaniam Somu |
10 Percent Owner |
Concesión de RSU |
20,000 |
$1.97 |
$39.4K |
20,000 |
| 2024-01-21 |
Hulme Allison |
Director |
Concesión de RSU |
20,000 |
$1.97 |
$39.4K |
20,000 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
